Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-Related Quality of Life for Patients with Relapsed/Refractory Multiple Myeloma ( RRMM): Final Data from the Phase 2 ELOQUENT-3 Trial

被引：2

作者：

Weisel, Katja ^{[1
]}

Dimopoulos, Meletios A. ^{[2
]}

San-Miguel, Jesus ^{[3
]}

Paner, Agne ^{[4
]}

Engelhardt, Monika ^{[5
]}

Taylor, Fiona ^{[6
]}

Lord-Bessen, Jennifer ^{[7
]}

Yao, David ^{[7
]}

Yip, Christine ^{[8
]}

Greenwood, Mike ^{[8
]}

Tang, Jackson ^{[7
]}

Cavo, Michele ^{[9
]}

机构：

[1] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Hematol & Bone Marrow Transplantat, Hamburg, Germany

[2] Natl & Kapodistrian Univ Athens, Sch Med, Athens, Greece

[3] Univ Navarra Clin, Pamplona, Spain

[4] Rush Univ Med Ctr, Chicago, IL USA

[5] Univ Med Ctr Freiburg, Freiburg, Germany

[6] Adelphi Values, Boston, MA USA

[7] Bristol Myers Squibb, Princeton, NJ USA

[8] Adelphi Values, Bollington, England

[9] Bologna Univ, IRCCS Azienda Osped Univ Bologna, Seragnoli Inst Hematol, Sch Med, Bologna, Italy

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-145310

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1662

引用

页数：6

共 50 条

[41] A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: The Japanese MM-011 trial
Ichinohe T.
Kuroda Y.
Okamoto S.
Matsue K.
Iida S.
Sunami K.
Komeno T.
Suzuki K.
Ando K.
Taniwaki M.
Tobinai K.
Chou T.
Kaneko H.
Iwasaki H.
Uemura C.
Tamakoshi H.
Zaki M.H.
Doerr T.
Hagiwara S.
Experimental Hematology & Oncology, 5 (1)
[42] A Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma
Berenson, James R.
Stampleman, Laura V.
Bessudo, Alberto
Rosen, Peter J.
Klein, Leonard M.
Woliver, Thomas
Flam, Marshall S.
Eshaghian, Shahrooz
Nassir, Youram
Swift, Regina A.
Vescio, Robert
BLOOD, 2014, 124 (21)
[43] LINKER-MM3, a phase 3, open-label, randomized study of linvoseltamab versus elotuzumab, pomalidomide, and dexamethasone (EPd) in relapsed/refractory multiple myeloma (RRMM)
Weisel, Katja
Hungria, Vania
Quach, Hang
Yoon, Sung-Soo
Rodriguez-Otero, Paula
Sinha, Arijit
Boyapati, Anita
Lyon, Charlotte
Moore, Vygngley
Inocencio, Tim
Harnett, James
Chi, Lei
Lorenc, Karen Rodriguez
Kroog, Glenn
Voorhees, Peter
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S63 - S64
[44] ELOQUENT-2: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LENALIDOMIDE/DEXAMETHASONE WITH OR WITHOUT ELOTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Dimopoulos, M.
Lonial, S.
Palumbo, A.
White, D.
Grosicki, S.
Spicka, I.
Walter-Croneck, A.
Moreau, P.
Mateos, M. -V.
Magen, H.
Belch, A.
Reece, D.
Beksac, M.
Spencer, A.
Oakervee, H.
Taniwaki, M.
Roellig, C.
Wu, K. L.
Singhal, A.
San Miguel, J.
Matsumoto, M.
Katz, J.
Bleickardt, E.
Poulart, V.
Richardson, P.
HAEMATOLOGICA, 2015, 100 : 173 - 173
[45] Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).
Lonial, Sagar
Dimopoulos, Meletios A.
Weisel, Katja
White, Darrell
Moreau, Philippe
Mateos, Maria-Victoria
San-Miguel, Jesus
Anderson, Kenneth Carl
Shpilberg, Ofer
Grosicki, Sebastian
Spicka, Ivan
Walter-Croneck, Adam
Magen, Hila
Belch, Andrew
Reece, Donna Ellen
Beksac, Meral
Shelat, Suresh
Sy, Oumar
Singhal, Anil K.
Richardson, Paul G.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[46] Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Richardson, Paul G.
Htut, Myo
Gasparetto, Cristina
Zonder, Jeffrey A.
Martin, Thomas G., III
Chen, Janice
Brooks, Christopher
McDonald, Peter
Rupprecht, Nicole
Wysowskyj, Halyna
Chauhan, Dharminder
Ray, Arghya
Anderson, Kenneth C.
Paba-Prada, Claudia E.
BLOOD, 2019, 134
[47] Isatuximab plus pomalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma (RRMM) in real-life context: interim analysis of the retrospective IMAGE study
Leleu, Xavier
Lafore, Radhia
Iaquinta, Daniel
Tekle, Christina
Rice, Megan
Decaux, Olivier
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S176 - S177
[48] Updated Results From DREAMM-3, a Phase 3 Study of Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Dexamethasone in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM)
Hungria, Vania T. M.
Weisel, Katja
Radinoff, Atanas
Delimpasi, Sosana
Mikala, Gabor
Masszi, Tamas
Li, Jian
Capra, Marcelo
Maiolino, Angelo
Pappa, Vasiliki
Chraniuk, Dominik
Osipov, Iurii
Leleu, Xavier
Low, Michael
Kouri, Fotini
Liboon, John
Brawley, Chris
Lewis, Eric
Tubel, Gabriela
Li, Mary
McKeown, Astrid
Roy-Ghanta, Sumita
Opalinska, Joanna
Dimopoulos, Meletios
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S261 - S262
[49] Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study
Dimopoulos, Meletios A.
Terpos, Evangelos
Boccadoro, Mario
Delimpasi, Sosana
Beksac, Meral
Katodritou, Eirini
Moreau, Philippe
Baldini, Luca
Symeonidis, Argiris
Bila, Jelena
Oriol, Albert
Mateos, Maria-Victoria
Einsele, Hermann
Orfanidis, Ioannis
Kampfenkel, Tobias
Liu, Weiping
Kosh, Michele
NamPhuong Tran
Carson, Robin
Sonneveld, Pieter
BLOOD, 2022, 140 : 7272 - 7274
[50] Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study
Schjesvold, Fredrik H.
Ludwig, Heinz
Delimpasi, Sossana
Robak, Pawel
Coriu, Daniel
Tomczak, Waldemar
Pour, Ludek
Spicka, Ivan
Dimopoulos, Meletios-Athanasios
Masszi, Tamas
Chernova, Natalia G.
Sandberg, Anna
Thuresson, Marcus
Norin, Stefan
Bakker, Nicolaas A.
Mateos, Maria-Victoria
Richardson, Paul G.
Sonneveld, Pieter
HAEMATOLOGICA, 2024, 109 (07) : 2331 - 2336

← 1 2 3 4 5 →